AstraZeneca eyes rare endocrinology market with $1.05B buyout of Amolyt Pharma
AstraZeneca is bulking up its late-stage rare disease pipeline by acquiring Amolyt Pharma in a $1.05 billion deal, bringing in a drug for “one of the largest known rare diseases.”
The Big Pharma will buy all of Amolyt’s outstanding shares, worth $800 million, at deal close. The French biotech could receive a further $250 million upon achieving an undisclosed regulatory milestone, according to an AstraZeneca release Thursday. Amolyt staff will join the company’s rare disease unit, Alexion Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
